Adding Pevonedistat to Azacitidine Does Not Improve Outcomes for Patients With MDS/CMML and AML
Researchers sought to determine whether adding pevonedistat to azacitidine would improve outcomes for patients with higher-risk MDS, CMML, or AML.
Leukemia
Guadecitabine Is Not Superior to Treatment Choice in Patients With Pretreated Acute Myeloid Leukemia
Researchers sought to determine whether guadecitabine would have an overall survival benefit for patients with relapsed/refractory acute myeloid leukemia.
Low-Dose Inotuzumab Ozogamicin May Be Safe and Effective in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Researchers sought to determine whether a low dose of inotuzumab ozogamicin would be safe and effective in patients with relapsed/refractory ALL.
Treatment With Azacitidine, Lenalidomide and Donor Lymphocyte Infusion in Myeloid Malignancies After Relapse Following Allo-SCT
Patients received up to 8 cycles of AZA and up to 3 cycle of DLI with increasing T cell dosages.
Zanubrutinib Improves PFS, But May Not Improve OS, in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Acalabrutinib May Reduce Toxicity in Chronic Lymphocytic Leukemia Compared With Ibrutinib
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia
Eight patients had a complete response within 1 month of infusion.
Patients With Acute Myeloid Leukemia May Have Suboptimal Outcomes Because of Fears of Treatment Side Effects
Researchers sought to determine whether patients with AML were being undertreated due to patient fear about side effects to treatment.
Phase 4 Feasibility Trial Is Evaluating At-Home Treatment of MRD-Positive BCP-ALL
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
Model May Identify Non-ETP T-ALL Patients at High Risk of Poor Response to Treatment
The model appears to predict minimal residual disease status.
